ADRB2 and breast carcinoma: Moreover, previous studies indicate an exacerbation in bone destruction after β2-AR agonism, in the immunosuppressed mice models of breast cancer bone metastasis as well as mice in in vivo and in vitro models of the pharmacological activation of β2-AR [14,51,52,53].